Preview

Проблемы Эндокринологии

Расширенный поиск

Федеральные клинические рекомендации по диагностике и лечению адренокортикального рака

https://doi.org/10.14341/probl201460251-67

Полный текст:

Аннотация

Определение гормональной активности и злокачественного потенциала - актуальнейший вопрос диагностики и выбора лечебной тактики при опухолях надпочечников. Адренокортикальный рак (АКР) - достаточно редкое заболевание, которое характеризуется плохими прогностическими показателями. Встречаемость АКР 0,5-2 случая на миллион населения, в структуре инциденталом надпочечников не более чем в 2-4% наблюдений. Для широкого обсуждения предлагается проект клинических рекомендаций по диагностике и лечению АКР, предназначенного для онкологов, хирургов, эндокринологов, специалистов по лучевой диагностике, патоморфологов и др.

Об авторах

Г А Мельниченко
ГБОУ ВПО «Первый московский государственный университет им. И.М. Сеченова» Минздрава России, Москва


И С Стилиди
ФГБУ «Российский онкологический научный центр им. Н.Н. Блохина» РАМН, Москва


Б Я Алексеев
ФГБУ «Московский научно-исследовательский онкологический институт им. П.А. Герцена» Минздрава России


В А Горбунова
ФГБУ «Российский онкологический научный центр им. Н.Н. Блохина» РАМН, Москва


Д Г Бельцевич
ФГБУ «Эндокринологический научный центр» Минздрава России, Москва


А О Райхман
ГБОУ ВПО «Первый московский государственный университет им. И.М. Сеченова» Минздрава России, Москва


Н С Кузнецов
ФГБУ «Эндокринологический научный центр» Минздрава России, Москва


Н В Жуков
ФГБУ «Московский научно-исследовательский онкологический институт им. П.А. Герцена» Минздрава России; ФГБУ «ФНКЦ детской гематологии, онкологии и иммунологии им. Д. Рогачева» Минздрава России, Москва


В Ю Бохян
ФГБУ «Российский онкологический научный центр им. Н.Н. Блохина» РАМН, Москва


Список литературы

1. Berruti A, Baudin E, Gelderblom H, Haak HR, Porpiglia F, Fassnacht M, Pentheroudakis G. Adrenal cancer: ESMO (European Society for Medical Oncology) Clinical Practice Guidelines for diagnosis, treatment and follow-up on behalf of the ESMO Guidelines Working Group. Ann Oncol 2012; 23: 131-138.

2. NCCN Clinical Practice Guidelines in Oncology. Neuroendocrine Tumor 2014; 1. 2014.

3. Schteingart DE, Doherty GM, Gauger PG et al. Management of patients with adrenal cancer: recommendations of an international consensus conference. Endocrinol Relat Cancer 2005; 12: 667.

4. Langer P, Cupisti K, Bartsch DK, Nies C, Goretzki PE, Rothmund M, Roher HD. Adrenal involvement in multiple endocrine neoplasia type 1. World J Surg 2002; 26: 891-896.

5. Gicquel C, Le Bouc Y. Molecular markers for malignancy in adrenocortical tumors. Horm Res 1997; 47: 269-272.

6. Бельцевич Д.Г., Кузнецов Н.С., Солдатова Т.В., Ванушко В.Э. Инциденталома надпочечников. // Эндокринная хирургия. - 2009. - №1 - С. 19-23. doi: 10.14341/2306-3513-2009-1-19-23

7. Bovio S, Cataldi A, Reimondo G et al. Prevalence of adrenal incidentaloma in a contemporary computerized tomography series. J Endocrinol Invest 2006; 29: 298-302.

8. Young WFJr. The Incidentally Discovered Adrenal Mass. N Engl J Med 2007; 356: 601-610.

9. Cawood TJ, Hunt PJ, O’Shea D, Cole D, Soule S. Recommended evaluation of adrenal incidentalomas is costly, has high false-positive rates and confers a risk of fatal cancer that is similar to the risk of the adrenal lesion becoming malignant; time for a rethink? Literature review. Eur J Endocrinol 2009; 161: 513-527.

10. Libe R, Dall’AC, Barbetta L, Baccarelli A, Beck-Peccoz P, Ambrosi B. Long-term follow-up study of patients with adrenal incidentalomas. Eur J Endocrinol 2002; 147: 489-494.

11. Kirkby-Bott J, Brunaud L, Mathonet M, Hamoir E, Kraimps JL, Trésallet C, et al. Ectopic hormone-secreting pheochromocytoma: a francophone observa- tional study. World J Surg 2012; 36(6): 1382-1388.

12. Li XG, Zhang DX, Li X, Cui XG, Xu DF, Li Y, Gao Y, Yin L, Ren JZ. Adrenocorticotropic hormone-producing pheochromocytoma: a case report and review of the literature. Chin Med J (Engl) 2012;125(6):1193-1196.

13. Cohade C, Broussaud S, Louiset E, Bennet A, Huyghe E, Caron P. Ectopic Cushing’s syndrome due to a pheochromocytoma: a new case in the post-partum and review of literature. Gynecol Endocrinol 2009; 25(9): 624-627.

14. Gardet V et al. Lessons from an unpleasant surprise: a biochemical strategy for the diagnosis of pheochromocytoma. J Hypertens 2001; 19: 1029-1035.

15. Nieman LK, Biller BMK, Findling JW, Newell-Price J, Savage MO, Stewart PM, Montori VM. The diagnosis of Cushing’s syndrome: an endocrine society clinical practice guideline J Clin Endocr Metabol 2008; 93(5): 1526-1540.

16. Newell-Price J, Trainer P, Besser M, Grossman A. The diagnosis and differential diagnosis of Cushing’s syndrome and pseudoCushing’s states. Endocr Rev 1998; 19: 647-672.

17. Pecori GF, Ambrogio AG, De Martin M, Fatti LM, Scacchi M, Cavagnini F. Specificity of first-line tests for the diagnosis of Cushing’s syndrome: assessment in a large series. J Clin Endocrinol Metabol 2007; 92: 4123-4129.

18. Tsagarakis S, Vassiliadi D, Thalassinos N. Endogenous subclinical hypercortisolism: diagnostic uncertainties and clinical implications. J Endocrinol Invest 2006; 29: 471-482.

19. Mitchell IC, Auchus RJ, Juneja K, Chang AY, Holt SA, Snyder WH 3rd, Nwariaku FE. «Subclinical Cushing’s syndrome» is not subclinical: improvement after adrenalectomy in 9 patients. Surgery 2007; 142(6): 900-905.

20. Mitchell IC, Auchus RJ, Juneja K, Chang AY, Holt SA, Snyder WH 3rd, Nwariaku FE. Subclinical Cushing’s syndrome is not subclinical: improvement after adrenalectomy in 9 patients. Surgery 2007; 142: 900-905.

21. Barzon L, Fallo F, Sonino N, Boscaro M. Development of overt Cushing’s syndrome in patients with adrenal incidentaloma. Eur J Endocrinol 2002; 146: 61-66.

22. Reincke M. Subclinical Cushing’s syndrome. Endocrinol Metabol Clin North Am 2000; 29: 43-56.

23. Pacak K. Preoperative management of the pheochromocytoma patient. J Clin Endocrinol Metabol 2007; 2278(92): 4069-4079.

24. Williams DT, Dann S, Wheeler MH. Phaeochromocytoma - views on current management. Eur J Surg Oncol 2003; 29: 483-490.

25. Kinney MA et al. Perioperative management of pheochromocytoma. J Cardiothorac Vasc Anesth 2002; 16: 359-369.

26. Pacak K et al. Recent advances in genetics, diagnosis, localization, and treatment of pheochromocytoma. Ann Intern Med 2001;134: 315-329.

27. Дедов И.И., Бельцевич Д.Г., Кузнецов Н.С., Мельниченко Г.А. Феохромоцитома. - М.: Практическая медицина, 2005; 216 с.

28. An Endocrine Society Clinical Practice Guidelines. Case Detection, Diagnosis, and Treatment of Patients with Primary Aldosteronism. J Clin Endocrinol Metabo 2008; 93(9): 3266-3281.

29. Трошина Е.А., Бельцевич Д.Г., Молашенко Н.В. Диагностика и дифференциальная диагностика первичного гиперальдостеронизма. // Клиническая медицина. - 2009. - №5 - С.15-20.

30. Mantero F, Terzolo M, Arnaldi G et al. A survey on adrenal incidentaloma in Italy. Study Group on Adrenal Tumors of the Italian Society of Endocrinology. J Clin Endocrinol Metabol 2000;85(2): 637-644.

31. Angeli A, Osella G, Ali A, Terzolo M. Adrenal incidentaloma: an overview of clinical and epidemiological data from the National Italian Study Group. Horm Res 1997; 47: 279-283.

32. Metser U, Miller E, Lerman H, Lievshitz G, Avital S, Even-Sapir E. 18F-FDG PET/CT in the Evaluation of Adrenal Masses. J Nucl Med 2006; 47(1): 32-37.

33. Blake M, Prakash P, Cronin C. PET/CT for Adrenal Assessment. Am J Roentgenol 2010; 195(2): 195.

34. Mackie GC, Shulkin BL, Ribeiro RC et al. Use of [18F]fluorodeoxyglucose positron emission tomography in evaluating locally recurrent and metastatic adrenocortical carcinoma. J Clin Endo- crinol Metabol 2006; 91: 2665.

35. Leboulleux S, Dromain C, Bonniaud G et al. Diagnostic and prognostic value of 18-fluorodeoxyglucose positron emission tomography in adrenocortical carcinoma: a prospective comparison with computed tomography. J Clin Endocrinol Metabol 2006; 91: 920.

36. Deandreis D, Leboulleux S, Caramella C et al. FDG PET in the management of patients with adrenal masses and adrenocortical carcinoma. Horm Cancer 2011; 2(6): 354-362.

37. Harisinghani MG, Maher MM, Hahn PF et al. Predictive value of benign percutaneous adrenal biopsies in oncology patients. Clin Radiol 2002; 57: 898-901.

38. Arellano RS, Harisinghani MG, Gervais DA, Hahn PF, Mueller PR. Imageguided percutaneous biopsy of the adrenal gland: review of indications, technique, and complications. Curr Probl Diagn Radiol 2003; 32: 3-10.

39. Welch TJ, Sheedy PF II, Stephens DH, Johnson CM, Swensen SJ. Percutaneous adrenal biopsy: review of a 10-year experience. Radiology 1994; 193: 341-344.

40. Casola G, Nicolet V, van Sonnenberg E et al. Unsuspected pheochromocytoma: risk of blood-pressure alterations during percutaneous adrenal biopsy. Radiology 1986; 159: 733-735.

41. McCorkell SJ, Niles NL. Fine-needle aspiration of catecholamineproducing adrenal masses: a possibly fatal mistake. AJR 1985; 145:113-114.

42. Pacak K, Eisenhofer G, Ahlman H, Bornstein SR, Gimenez-Roqueplo AP, Grossman AB, et al. Pheochromocytoma: recommendations for clinical practice from the First International Symposium. Nat Clin Pract Endocrinol Metabol 2007; 3: 92-102.

43. Saeger W, Fassnacht M, Chita R. High Diagnostic Accuracy of Adrenal CoreBiopsy: Results of the German and Austrian Adrenal Network Multicenter Trial in 220 Consecutive Patients. Human Pathol 2003; 34(2): 180-186.

44. Dackiw AP, Lee JE, Gagel RF, Evans DB. Adrenal cortical carcinoma. World J Surg 2001; 25: 914-926.

45. Ng L, Libertino JM. Adrenocortical carcinoma: diagnosis, evaluation and treatment. J Urol 2003; 169: 5-11.

46. Miller BS, Gauger PG, Hammer GD et al. Proposal for modification of the ENSAT staging system for adrenocortical carcinoma using tumor grade. Langenbecks Arch Surg 2010; 395: 955.

47. Fassnacht M, Johanssen S, Quinkler M et al. Limited prognostic value of the 2004 International Union Against Cancer staging classification for adrenocortical carcinoma: proposal for a Revised TNM Classification. Cancer 2009; 115: 243.

48. Wängberg B, Khorram-Manesh A, Jansson S et al. The long-term survival in adrenocortical carcinoma with active surgical management and use of monitored mitotane. Endocrinol Relat Cancer 2010; 17: 265.

49. Allolio B, Fassnacht M. Clinical review: adrenocortical carcinoma: clinical update. J Clin Endocrinol Metabol 2006; 91: 2027.

50. Филимонюк А.В., Харченко Н.В., Леонов Б.И., Смирнова Е.А., Антонов А.К., Смелкова Н.И. Непосредственные и отдаленные результаты хирургического лечения больных адренокортикальным раком. // Вестник новых медицинских технологий (электронное издание). - 2013. - №1. Доступно по адресу: http://medtsu.tula.ru/VNMT/Bulletin/E2013-1/4286.pdf doi: 10.12737/issn.1609-2163

51. Reibetanz J, Jurowich C, Erdogan I et al. Impact of lymphadenectomy on the oncologic outcome of patients with adrenocortical carcinoma. Ann Surg 2012; 255: 363.

52. Gaujoux S, Brennan MF. Recommendation for standardized surgical management of primary adrenocortical carcinoma. Surgery 2012; 152(1): 123-132.

53. Porpiglia F, Miller BS, Manfredi M et al. A debate on laparoscopic versus open adrenalectomy for adrenocortical carcinoma. Horm Cancer 2011; 2(6): 372.

54. Brix D, Allolio B, Fenske W et al. Laparoscopic versus open adrenalectomy for adrenocortical carcinoma: surgical and oncologic outcome in 152 patients. Eur Urol 2010; 58: 609.

55. Donatini G, Caiazzo R, Do Cao Ch et al. Long-Term Survival After Adrenalectomy for Stage I/II Adrenocortical Carcinoma (ACC): A Retrospective Comparative Cohort Study of Laparoscopic Ver- sus Open Approach. Ann Surg Oncol 2014; 21: 284-291.

56. McCauley LR, Nguyen MM. Laparoscopic radical adrenalectomy for cancer: long-term outcomes. Curr Opin Urol 2008; 18: 134.

57. Gonzalez RJ, Shapiro S, Sarlis N, Vassilopoulou-Sellin R, Perrier ND, Evans DB, Lee JE. Laparoscopic resection of adrenal cortical carcinoma: a cautionary note. Surgery. 2005;138(6):1078.

58. Miller BS, Gauger PG, Hammer GD, Doherty GM. Resection of adrenocortical carcinoma is less complete and local recurrence occurs sooner and more often after laparoscopic adrenalectomy than after open adrenalectomy. Surgery 2012; 152: 1150-1157.

59. Leboulleux S, Deandreis D, Ghuzlan AA, Auperin A, Goere D, Dromain C, Elias D, Caillou B, Travagli JP, De Baere T, Lumbroso J, Young J, Schlumberger M, Baudin E. Adrenocortical carcinoma: is the surgical approach a risk factor of peritoneal сarcinomatosis? Eur J Endocrinol 2010; 162: 1147-1153.

60. Schulick RD, Brennan MF. Long-term survival after complete resection and repeat resection in patients with adrenocortical carcinoma. Ann Surg Oncol 1999; 6(8): 719-726.

61. Icard P, Chapuis Y, Andreassian B, Bernard A, Proye C. Adrenocortical carcinoma in surgically treated patients: a retrospective study on 156 cases by the French Association of Endocrine Surgery. Surgery 1992; 112(6): 972-979.

62. Bellantone R, Ferrante A, Boscherini M et al. Role of reoperation in recurrence of adrenal cortical carcinoma: results from 188 cases collected in the Italian National Registry for Adrenal Cortical Carcinoma. Surgery 1997; 122: 1212-1218.

63. Porpiglia F, Fiori C, Scarpa RM, Daffara F, De Francia S, Zaggia B, Angeli A, Berruti A, Terzolo M. The role of surgery in the management of recurrent adrenocortical carcinoma: results of a retrospective study. Eur Urol 2009; 8(4): 305.

64. Weiss LM. Am J Surg Pathol 1984; 8(3): 163-169.

65. Lau SK, Weiss LM. The Weiss system for evaluating adrenocortical neoplasms: 25 years later. Hum Pathol 2009; 40(6): 757-768.

66. van Slooten H, Schaberg A, Smeenk D, Moolenar AJ. Morphologic characteristics of benign and malignant adrenocortical tumors. Cancer 1985; 55(4): 766-773.

67. Blanes A et al. Histologic criteria for adrenocortical proliferative lesions: value of mitotic figure variability. Am J Clin Pathol 2007;127(3): 398-408.

68. Филиппова О.В., Хмельницкая Н.М. Адренокортикальный рак: клинические проявления и морфологическая диагностика. // Медицинский альманах. - 2011. - №5 - С. 113-116.

69. Hahner S, Fassnacht M. Mitotane for adrenocortical carcinoma treatment. Curr Opin Investig Drugs 2005;6(4):386-394.

70. Schteingart DE. Conventional and novel strategies in the treatment of adrenocortical cancer. Braz J Med Biol Res 2000; 33: 1197-1200.

71. Lubitz JA, Freeman L, Okun R. Mitotane use in inoperable adrenalcortical carcinoma. JAMA 1973; 223: 1109-1112.

72. van Slooten H, Moolenaar AJ, van Seters AP, Smeenk D. The treatment of adrenocortical carcinoma with o,p_-DDD: prognostic implications of serum level monitoring. Eur J Cancer Clin Oncol 1984; 20: 47-55.

73. Haak HR, Hermans J, van de Velde CJ, Lentjes EG, Goslings BM, Fleuren GJ, Krans HM. Optimal treatment of adrenocortical carcinoma with mitotane: results in a consecutive series of 96 patients. Br J Cancer 1994; 69: 947-951.

74. Baudin E, Pellegriti G, Bonnay M, Penfornis A, Lanche A, Vassal G, Schlumberger M. Impact of monitoring plasma 1,1-dichlorodiphenildichloroethane (o,p_DDD) levels on the treatment of patients with adrenocortical carcinoma. Cancer 2001; 92: 1385-1392.

75. Heilmann P, Wagner P, Nawroth PP, Ziegler R. Therapy of the adrenocortical carcinoma with Lysodren (o,p’-DDD). Therapeutic management by monitoring o,p_DDD blood levels. Med Klin 2001; 96: 371-377.

76. Becker D, Schumacher OP. o,p’DDD therapy in invasive adrenocortical carcinoma. Ann Intern Med 1975; 82: 677-679.

77. Boven E, Vermorken JB, van Slooten H, Pinedo HM. Complete response of metastasized adrenal cortical carcinoma with o,p-DDD. Case report and literature review. Cancer 1984; 53: 26-29.

78. Krzisnik C, Petric G, Jereb B. Complete response of metastatic adrenal cortical carcinoma to o,p-DDD in a child. Pediatr Hematol Oncol 1988; 5: 65-69.

79. Lim MC, Tan YO, Chong PY, Cheah JS. Treatment of adrenal cortical carcinoma with mitotane: outcome and complications. Ann Acad Med Singapore 1990.

80. Decker R A, Kuehner ME. Adrenocortical carcinoma. Am Surg 1991; 57: 502-513.

81. Remond S, Bardet S, Charbonnel B. Complete and lasting remission of a metastatic malignant adrenocortical carcinoma under treatment with OP- DDD alone. Presse Med 1992; 21: 865.

82. Ilias I, Alevizaki M, Philippou G, Anastasiou E, Souvatzoglou A. Sustained remission of metastatic adrenal carcinoma during long-term administration of low-dose mitotane. J Endocrinol Invest 2001; 24: 532-535.

83. Allolio B, Hahner S, Weismann D, Fassnacht M. Management of adrenocortical carcinoma. Clin Endocrinol (Oxf) 2004; 60: 273-287.

84. Hague RV, May W, Cullen DR. Hepatic microsomal enzyme induction and adrenal crisis due to o,p_DDD therapy for metastatic adrenocortical carcinoma. Clin Endocrinol (Oxf) 1989; 31: 51-57.

85. Dickstein G. Is there a role of low dose of mitotane as adjuvant therapy in adrenocortical carcinoma? J Clin Endocrinol Metabol 1999; 84: 1488-1489.

86. Vassilopoulou-Sellin R, Guinee VF, Klein MJ, Taylor SH, Hess KR, Schultz PN, Samaan NA. Impact of adjuvant mitotane on the clinical course of patients with adrenocortical cancer. Cancer 1993; 71: 3119-3123.

87. Terzolo M, Angeli A, Fassnacht M. Adjuvant mitotane treatment for adrenocortical carcinoma. N Engl J Med 2007; 356(23): 2372.

88. Clinical trials gov. identifier NCT00777244, start 2008, update 2013.

89. Fassnacht M, Libé R, Kroiss M, Allolio B. Adrenocortical carcinoma: a clinician’s update. Nat Rev Endocrinol 2011; 7: 323.

90. Cordon-Cardo C, O’Brien JP, Boccia J, Casals D, Bertino JR, Melamed MR. Expression of the multidrug resistance gene product (P-glycoprotein) in human normal and tumor tissues. J Histochem Cytochem 1990; 38: 1277-1287.

91. Flynn SD, Murren JR, Kirby WM, Honig J, Kan L, Kinder BK. P-glycoprotein expression and multidrug resistance in adrenocortical carcinoma. Surgery 1992; 112: 981-986.

92. Goldstein LJ, Galski H, Fojo A, Willingham M, Lai SL, Gazdar A, et al. Expression of a multidrug resistance gene in human cancers. J Natl Cancer Inst 1989; 81: 116-124.

93. Fridborg H, Larsson R, Juhlin C, Rastad J, Akerstrom G, Backlin K, Nygren P. P-glycoprotein expression and activity of resistance modifying agents in primary cultures of human renal and adrenocortical carcinoma cells. Anticancer Res 1994; 14: 1009-1016.

94. Haak HR, van Seters AP, Moolenaar AJ, Fleuren GJ. Expression of P-glycoprotein in relation to clinical manifestation, treatment and prognosis of adrenocortical cancer. Eur J Cancer 1993; 29A(7):1036-1038.

95. Fassnacht M, Terzolo M, Allolio B et al. Combination chemotherapy in advanced adrenocortical carcinoma. FIRM-ACT Study Group. N Engl J Med 2012; 366(23): 2189.

96. Fassnacht M, Kroiss M, Allolio B. Update in Adrenocortical Carcinoma. J Clin Endocrinol Metabol 2013; 98(12): 4551-4564.

97. Icard P, Goudet P, Charpenay C. Adrenocortical carcinomas: surgical trends and results of a 253-patient series from the French Association of Endocrine Surgeons Study Group. World J Surg 2001;25(7): 891-897.

98. Crucitti F, Bellantone R, Ferrante A, Boscherini M, Crucitti P. The Italian Registry for Adrenal Cortical Carcinoma: analysis of a multiinstitutional series of 129 patients. The ACC Italian Registry Study Group. Surgery 1996; 119: 161-170.

99. Pommier RF, Brennan MF. An eleven-year experience with adrenocortical carcinoma. Surgery 1992; 112: 963-970; discussion 970-971.

100. Soreide JA, Brabrand K, Thoresen SO. Adrenal cortical carcinoma in Norway, 1970-1984. World J Surg 1992; 16: 663-667; discussion 668.

101. Vassilopoulou-Sellin R, Schultz PN. Adrenocortical carcinoma. Clinical outcome at the end of the 20th century. Cancer 2001; 92:1113-1121.


Для цитирования:


Мельниченко Г.А., Стилиди И.С., Алексеев Б.Я., Горбунова В.А., Бельцевич Д.Г., Райхман А.О., Кузнецов Н.С., Жуков Н.В., Бохян В.Ю. Федеральные клинические рекомендации по диагностике и лечению адренокортикального рака. Проблемы Эндокринологии. 2014;60(2):51-67. https://doi.org/10.14341/probl201460251-67

For citation:


Melnichenko G.A., Stilidi I.S., Alekseev B.Y., Gorbunova V.A., Beltsevich D.G., Raikhman A.O., Kuznetsov N.S., Zhukov N.V., Bokhyan V.Yu. Federal clinical practice guidelines on the diagnostics and treatment of adrenocortical cancer. Problems of Endocrinology. 2014;60(2):51-67. (In Russ.) https://doi.org/10.14341/probl201460251-67

Просмотров: 190


ISSN 0375-9660 (Print)
ISSN 2308-1430 (Online)